Upvote
Downvote
Chief Scientific Officer
Share Job
- Suggest Revision
- Experience working in gene therapy, gene editing/CRISPR, and/or RNAi required
- Kelonia Therapeutics is a preclinical, biotechnology company pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS).
- By enabling precisely targeted, highly efficient, manufacturable off-the-shelf in vivo delivery, Kelonias technology has the potential to revolutionize gene therapy and dramatically expand the impact and reach of genetic medicines to every patient in need and can be applied to a broad range of diseases.
- In addition, Kelonia recently announced a research collaboration and license agreement with Astellas Pharma to develop novel immuno-oncology therapeutics.
- With this agreement, Kelonia will receive $40 million upfront for the first program, an additional $35 million should Astellas exercise its options for a second program, potential milestones and contingency payments approaching $800 million in total, and R&D funding for work performed in the collaboration.
Active Job
Updated 21 days agoSimilar Job
Relevance
Active